CDK19 and ovarian cancer: The loss‐of‐function studies indicated a dependency of the growth of several cancers, including osteosarcoma, breast, multiple myeloma and ovarian, on CDK11, and in liposarcoma and ovarian cancer cells it also enhanced the cytotoxic effect of doxorubicin and paclitaxel, respectively.4, 5